Anthony Petrone
Stock Analyst at Mizuho
(3.84)
# 661
Out of 4,876 analysts
171
Total ratings
50.4%
Success rate
8.34%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Outperform | $60 → $65 | $50.86 | +27.80% | 2 | Jun 13, 2025 | |
| EMBC Embecta | Maintains: Neutral | $15 → $13 | $9.64 | +34.85% | 2 | May 23, 2025 | |
| MDT Medtronic | Maintains: Outperform | $100 → $98 | $86.02 | +13.93% | 5 | May 22, 2025 | |
| GKOS Glaukos | Maintains: Outperform | $200 → $175 | $101.42 | +72.55% | 8 | Apr 16, 2025 | |
| SENS Senseonics Holdings | Initiates: Outperform | $2 | $0.49 | +304.78% | 1 | Apr 10, 2025 | |
| TNDM Tandem Diabetes Care | Initiates: Neutral | $20 | $18.94 | +5.60% | 1 | Apr 10, 2025 | |
| DXCM DexCom | Initiates: Outperform | $85 | $86.33 | -1.54% | 1 | Apr 10, 2025 | |
| EXAS Exact Sciences | Initiates: Outperform | $60 | $53.65 | +11.84% | 1 | Apr 10, 2025 | |
| ALC Alcon | Maintains: Outperform | $115 → $120 | $87.81 | +36.66% | 9 | Mar 28, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $54 → $58 | $40.35 | +43.74% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $60 | $45.75 | +31.15% | 8 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $87 | $65.01 | +33.83% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $275 → $250 | $119.47 | +109.26% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $110 | $106.53 | +3.26% | 8 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $115 → $130 | $134.38 | -3.26% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $14 | $18.16 | -22.91% | 6 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $70 | $40.93 | +71.02% | 6 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $55 | $16.92 | +225.06% | 7 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $100 | $81.49 | +22.71% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $74.38 | +41.17% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $105 | $78.21 | +34.25% | 7 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $215 | $255.16 | -15.74% | 15 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $250 | $132.41 | +88.81% | 6 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $5.94 | +135.69% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $103 → $115 | $71.14 | +61.65% | 14 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $533.71 | -26.93% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $82.57 | -18.86% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $115 | $73.80 | +55.83% | 14 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $91.46 | +91.34% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $8.58 | +191.38% | 3 | May 13, 2020 |
Guardant Health
Jun 13, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $50.86
Upside: +27.80%
Embecta
May 23, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $9.64
Upside: +34.85%
Medtronic
May 22, 2025
Maintains: Outperform
Price Target: $100 → $98
Current: $86.02
Upside: +13.93%
Glaukos
Apr 16, 2025
Maintains: Outperform
Price Target: $200 → $175
Current: $101.42
Upside: +72.55%
Senseonics Holdings
Apr 10, 2025
Initiates: Outperform
Price Target: $2
Current: $0.49
Upside: +304.78%
Tandem Diabetes Care
Apr 10, 2025
Initiates: Neutral
Price Target: $20
Current: $18.94
Upside: +5.60%
DexCom
Apr 10, 2025
Initiates: Outperform
Price Target: $85
Current: $86.33
Upside: -1.54%
Exact Sciences
Apr 10, 2025
Initiates: Outperform
Price Target: $60
Current: $53.65
Upside: +11.84%
Alcon
Mar 28, 2025
Maintains: Outperform
Price Target: $115 → $120
Current: $87.81
Upside: +36.66%
Tarsus Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $40.35
Upside: +43.74%
Feb 26, 2025
Maintains: Outperform
Price Target: $70 → $60
Current: $45.75
Upside: +31.15%
Nov 5, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $65.01
Upside: +33.83%
Nov 1, 2024
Maintains: Neutral
Price Target: $275 → $250
Current: $119.47
Upside: +109.26%
Oct 24, 2024
Maintains: Outperform
Price Target: $100 → $110
Current: $106.53
Upside: +3.26%
Oct 17, 2024
Maintains: Neutral
Price Target: $115 → $130
Current: $134.38
Upside: -3.26%
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $18.16
Upside: -22.91%
Jun 6, 2024
Maintains: Buy
Price Target: $65 → $70
Current: $40.93
Upside: +71.02%
May 8, 2024
Maintains: Buy
Price Target: $53 → $55
Current: $16.92
Upside: +225.06%
May 3, 2024
Maintains: Buy
Price Target: $90 → $100
Current: $81.49
Upside: +22.71%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $74.38
Upside: +41.17%
Apr 11, 2024
Maintains: Buy
Price Target: $95 → $105
Current: $78.21
Upside: +34.25%
Mar 27, 2024
Maintains: Buy
Price Target: $215
Current: $255.16
Upside: -15.74%
Mar 27, 2024
Maintains: Buy
Price Target: $250
Current: $132.41
Upside: +88.81%
Mar 1, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $5.94
Upside: +135.69%
Mar 1, 2024
Maintains: Buy
Price Target: $103 → $115
Current: $71.14
Upside: +61.65%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $533.71
Upside: -26.93%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $82.57
Upside: -18.86%
Feb 8, 2023
Maintains: Buy
Price Target: $110 → $115
Current: $73.80
Upside: +55.83%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $91.46
Upside: +91.34%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $8.58
Upside: +191.38%